Emerging therapeutic options for the treatment of patients with symptomatic asthma (Q26800791)

Annals of Allergy, Asthma & Immunology

Europe PubMed Central

title

Emerging therapeutic options for the treatment of patients with symptomatic asthma (English)

0 references

0 references

R Andrew McIvor

1

0 references

language of work or name

English

0 references

publication date

October 2015

0 references

published in

0 references

volume

115

0 references

issue

4

0 references

page(s)

265-271.e5

0 references

cites work

Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Changing face of β2-adrenergic and muscarinic receptor therapies in asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A review of the development of Respimat Soft Mist Inhaler

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Predictors of response to tiotropium versus salmeterol in asthmatic adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Efficacy and safety of roflumilast in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium bromide step-up therapy for adults with uncontrolled asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Lebrikizumab treatment in adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium in asthma poorly controlled with standard combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Dupilumab in persistent asthma with elevated eosinophil levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

The global burden of asthma: executive summary of the GINA Dissemination Committee report

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Single-dose pharmacokinetics of roflumilast in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A new perspective on concepts of asthma severity and control.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Muscarinic receptor signaling in the pathophysiology of asthma and COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

The Preventable Burden of Productivity Loss Due to Suboptimal Asthma Control

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Efficacy of anticholinergic drugs in asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

Understanding patients with asthma and COPD: insights from a European study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

The role of tiotropium in the management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ANAI.2015.07.011

7 January 2021

10.1016/J.ANAI.2015.07.011

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_46lbdrz6ifej5gr6ywg6ahmy7e

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/46lbdrz6ifej5gr6ywg6ahmy7e

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

26254973

1 reference

Consolidated OpenCitations Corpus – April 2017